Globus Medical reports Q2 2026 revenue of $789.6 million, up 6%

Globus Medical (NYSE: GMED) reported Q2 2026 revenue of $789.6 million, up 6% year-over-year (9% excluding Nevro), with spine up 7% and International Spine up 14%. Non-GAAP EPS rose 56% to $1.34, adjusted EBITDA margin improved to 35.4%, and the company repurchased $136 million of shares.

Detected & updated continuously · Source: Nebula